A preliminary study on biological features of 188Re-anti-hepatocellular carcinoma immuno-magnetite nanoparticle

Objectives To study on the immunocompetence, biological distribution in vivo, liver targeting and tumor inhibition of ¹⁸⁸Re-immunomagnetite nanoparticle(¹⁸⁸Re-HMN), thus to provide a biological-magnetic double targeting radiotherapy for primary hepatocellular carcinoma.

Methods By setting up ¹⁸⁸ReO₄^- group, ¹⁸⁸Re-Hepama group and ¹⁸⁸Re-magnetite nanoparticle group, the distributions of ¹⁸⁸Re-HMN in liver, spleen, kidney, lung, stomach, blood, brain, femoral bone and muscle were investigated 4h, 24h after the particles were injected into tail vein of Kunming mouse. The particles were also injected into New Zealand rabbit, the hepatic magnetic targeting in vivo was studied when magnetic field was attached or not onto hepatic region. MMT method was adopted to study the inhibiting effects of 4 ¹⁸⁸Re markers on hepatoma cell strain SMMC-7721.

Results After the particles were intravenously injected into mice for 4h and 24 h, there was significantly difference in ¹⁸⁸Re-HMN group compared to ¹⁸⁸ReO₄^- group, ¹⁸⁸R-Hepama group and ¹⁸⁸Re-magnetite nanoparticle group (ρ<0.01), and ¹⁸⁸Re-HMN group had the most uptake. After magnetic field applied on left lateral lobe , in ¹⁸⁸Re-HMN group, and radio-activity of magnetic field was obviously increased compared to that of non-magnetic field (ρ=0.000), and the radio-activity ratio of them was 1.87. The inhibition rates against hepatocellular carcinoma SMMC-7721 cells of ¹⁸⁸Re-HMN group were significantly higher than those groups (P<0.05).

Conclusions ¹⁸⁸Re-immuno-magnetite nanoparticle provides a helpful prospect for biological magnetic targeting therapy against primary hepatocellular carcinoma.